50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Pfizer vs Moderna battle over COVID vaccine patents begins in UK

Published 04/23/2024, 07:23 AM
Updated 04/23/2024, 07:32 AM
© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
PFE
-
MRNA
-
BNTX
-

By Sam Tobin

LONDON (Reuters) - Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) asked a London court to revoke rival Moderna (NASDAQ:MRNA)'s patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.

Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed.

The competing lawsuits over the companies' two vaccines, which helped save millions of lives and made the companies billions of dollars, are just one strand of ongoing litigation around the world which focuses on messenger RNA (mRNA) technology.

Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.

U.S.-based Moderna is seeking damages for alleged infringement of its patents by Pfizer and BioNTech's Comirnaty shot on sales since March 2022.

Pfizer made $11.2 billion in sales from Comirnaty last year, while Moderna earned $6.7 billion from its vaccine Spikevax, illustrating the potentially huge sums at stake.

Pfizer and BioNTech, however, are asking the High Court to revoke Moderna's patents, arguing that Moderna's developments of mRNA technology were obvious improvements on previous work.

© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo

The London lawsuits have been split into three separate trials, with one due to consider Moderna's 2020 pledge not to enforce its vaccine-related patents during the pandemic starting next.

Pfizer, BioNTech and Moderna are also involved in parallel proceedings in Germany, the Netherlands, Belgium and the United States, much of which has been put on hold, as well as at the European Patent Office.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.